SCHEMBL2201139

SCHEMBL2201139

CC1(c2ccccc2)CNCC[N]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.44
BACE1 P56817 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
OPRM1 P35372 2/20 0.38
KDM1A O60341 1/20 0.34
MAOA P21397 1/20 0.34
CACNA1F O60840 1/20 0.33
AR P10275 1/20 0.33
PDE4A P27815 1/20 0.33
SCN1A P35498 1/20 0.33
SCN4A P35499 1/20 0.33
SCN7A Q01118 1/20 0.33
CACNA1D Q01668 1/20 0.33
KCNH2 Q12809 1/20 0.33
CACNA1S Q13698 1/20 0.33
CACNA1C Q13936 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN9A Q15858 1/20 0.33
SCN2A Q99250 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5944261 0.84 CYP19A1 (0.32)
SCHEMBL2203810 0.77 OPRM1 (0.40) HTR2ABACE1NPSR1GPR55OPRM1
SCHEMBL654291 0.77 HTR2A (0.47) HTR2ABACE1NPSR1GPR55OPRM1
SCHEMBL4436585 0.74 HTR2A (0.44) HTR2ABACE1OPRM1MAOACACNA1F
SCHEMBL1254663 0.74 HTR2A (0.44) HTR2AOPRM1CACNA1FARPDE4A
SCHEMBL10682672 0.74 HTR2A (0.44) HTR2AOPRM1CACNA1FARPDE4A
SCHEMBL1255254 0.74 HTR2A (0.41) HTR2ANPSR1GPR55OPRM1CACNA1F
SCHEMBL6361063 0.71 HTR2A (0.39) HTR2AOPRM1KDM1AMAOAKCNH2
SCHEMBL4722907 0.70 OPRM1 (0.38) HTR2AOPRM1OPRK1OPRL1
SCHEMBL2486825 0.70 BACE1 (0.38) HTR2ABACE1NPSR1GPR55MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809369-B2 Tetrahydroquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2014-08-19 US claimed
EP-2558449-B1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-05 EP claimed
EP-2668165-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2013-12-04 EP claimed
US-8586747-B2 3,3-dimethyl tetrahydroquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2013-11-19 US claimed
EP-2558449-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2013-02-20 EP claimed
US-20130023518-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES Hoffmann-La Roche Inc (US) 2013-01-24 US claimed
US-8344137-B2 3,3-dimethyl tetrahydroquinoline derivatives HOFFMAN-LA ROCHE INC. (US) 2013-01-01 US claimed
WO-2012101068-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-08-02 WO claimed
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 US claimed
US-20110257151-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES HUA MEDICINE (KY) 2011-10-20 US claimed
US-7439238-B2 Antiparasitic artemisinin derivatives (endoperoxides) THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (HK) 2008-10-21 US claimed
US-20070191354-A1 Antiparasitic artemisinin derivatives (endoperoxides) BAYER AKTIENGESELLSCHAFT (DE) 2007-08-16 US claimed
US-20070021409-A1 Antiparasitic artemisinin derivatives (endoperoxides) BAYER AKTIENGESELLSCHAFT (DE) 2007-01-25 US claimed
EP-1095042-B9 ANTIPARASITIC ARTEMISININ DERIVATIVES (ENDOPEROXIDES) BAYER HEALTHCARE AG (DE) 2006-07-05 EP claimed
EP-1655302-A2 ANTIPARASITIC ARTEMISININ DERIVATIVES (ENDOPEROXIDES) Bayer HealthCare AG (DE) 2006-05-10 EP claimed
EP-1095042-B1 ANTIPARASITIC ARTEMISININ DERIVATIVES (ENDOPEROXIDES) BAYER HEALTHCARE AG (DE) 2005-12-28 EP claimed
EP-1095042-A1 ANTIPARASITIC ARTEMISININ DERIVATIVES (ENDOPEROXIDES) Bayer Aktiengesellschaft (DE) 2001-05-02 EP claimed
WO-2000004024-A1 ANTIPARASITIC ARTEMISININ DERIVATIVES (ENDOPEROXIDES) BAYER AKTIENGESELLSCHAFT (DE) 2000-01-27 WO claimed
EP-0543919-B1 USE OF HETEROCYCLIC AMINO-ALCOHOL COMPOUNDS IN THE MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF CNS DISEASES SEARLE & CO (US) 1996-04-10 EP claimed
US-4107437-A SEDATIVES, ANTIARRHYTHMIA AGENTS PARCOR (FR) 1978-08-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES RAB1A, RABL3, RAB7A HTR2A 1107/4885BACE1 2896/4885NPSR1 766/4885
US-20070021409-A1 Antiparasitic artemisinin derivatives (endoperoxides) DHPS, CASP10, FECH HTR2A 3418/4885BACE1 3516/4885NPSR1 2565/4885
US-20070191354-A1 Antiparasitic artemisinin derivatives (endoperoxides) DHPS, CASP10, FECH HTR2A 3418/4885BACE1 3516/4885NPSR1 2565/4885
US-20110257151-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES QDPR, PRMT3, PRMT1 HTR2A 402/4885BACE1 2662/4885NPSR1 853/4885
US-20130023518-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES QDPR, PRMT3, PRMT1 HTR2A 402/4885BACE1 2662/4885NPSR1 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.